Involvement of Bile Acid Metabolism and Gut Microbiota in the Amelioration of Experimental Metabolism-Associated Fatty Liver Disease by Nobiletin
Molecules · 23.02.2024 · 29 (5) · 976
DOI: 10.3390/molecules29050976 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 23.02.2024. Verfasst von Hongling Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Traditional Chinese Pharmacology, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Non-alcoholic Fatty Liver Disease, Flavones. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Sichuan Administration of Traditional Chinese Medicine, Sichuan Province Science and Technology Support Program, Fundamental Research Funds for Sichuan Provincial Scientific Research Institutes.
Abstract (Originalsprache)
Metabolism-associated fatty liver disease (MAFLD), a growing health problem worldwide, is one of the major risks for the development of cirrhosis and liver cancer. Oral administration of nobiletin (NOB), a natural citrus flavonoid, modulates the gut microbes and their metabolites in mice. In the present study, we established a mouse model of MAFLD by subjecting mice to a high-fat diet (HFD) for 12 weeks. Throughout this timeframe, NOB was administered to investigate its potential benefits on gut microbial balance and bile acid (BA) metabolism using various techniques, including 16S rRNA sequencing, targeted metabolomics of BA, and biological assays. NOB effectively slowed the progression of MAFLD by reducing serum lipid levels, blood glucose levels, LPS levels, and hepatic IL-1β and TNF-α levels. Furthermore, NOB reinstated diversity within the gut microbial community, increasing the population of bacteria that produce bile salt hydrolase (BSH) to enhance BA excretion. By exploring further, we found NOB downregulated hepatic expression of the farnesoid X receptor (FXR) and its associated small heterodimer partner (SHP), and it increased the expression of downstream enzymes, including cholesterol 7α-hydroxylase (CYP7A1) and cytochrome P450 27A1 (CYP27A1). This acceleration in cholesterol conversion within the liver contributes to mitigating MAFLD. The present findings underscore the significant role of NOB in regulating gut microbial balance and BA metabolism, revealing that long-term intake of NOB plays beneficial roles in the prevention or intervention of MAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Traditional Chinese Pharmacology, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
- Laboratory Animal Center Affiliate from Research Office, Sichuan Academy of Chinese Medicine Sciences, Chengdu 610041, China.
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau 999078, China.
Förderung
- The Sichuan Administration of Traditional Chinese Medicine
- Sichuan Province Science and Technology Support Program
- Fundamental Research Funds for Sichuan Provincial Scientific Research Institutes
Zitieren
APA
Xu, H., Yuan, M., Niu, K., Yang, W., Jiang, M., Zhang, L., & Zhou, J. (2024). Involvement of Bile Acid Metabolism and Gut Microbiota in the Amelioration of Experimental Metabolism-Associated Fatty Liver Disease by Nobiletin. Molecules, 29(5), 976. https://doi.org/10.3390/molecules29050976
Vancouver
Xu H, Yuan M, Niu K, Yang W, Jiang M, Zhang L, et al. Involvement of Bile Acid Metabolism and Gut Microbiota in the Amelioration of Experimental Metabolism-Associated Fatty Liver Disease by Nobiletin. Molecules. 2024;29(5):976. doi:10.3390/molecules29050976
BibTeX
@article{Xu2024,
author = {Xu, Hongling and Yuan, Mingming and Niu, Kailin and Yang, Wei and Jiang, Maoyuan and Zhang, Lei and Zhou, Jing},
title = {Involvement of Bile Acid Metabolism and Gut Microbiota in the Amelioration of Experimental Metabolism-Associated Fatty Liver Disease by Nobiletin},
journal = {Molecules},
year = {2024},
volume = {29},
number = {5},
pages = {976},
doi = {10.3390/molecules29050976}
}
EUVIMED